The Evolving Role of PI3K Inhibitors for the Management of Hematologic Malignancies: Integration of Recent Data Sets Into Clinical Practice is a .. Read more platform where renowned experts in hematologic malignancies will review the rationale for PI3K inhibitors in the treatment of chronic lymphocytic leukemia and lymphoma, as well as assess the recent clinical trial available. The experts will provide insights on the identification of patients likely to achieve greatest clinical benefit with PI3K inhibitors, the practical implications of utilizing PI3K inhibitors in the clinic, and the impact of PI3K inhibitors on patients with hematologic malignancies.
- Share your Experience
More Events From The Organizer
- Exploring the Practicalities o..26 Jan 2021Online